{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-011430","form_type":"8-K","ticker":"GUTS","cik":"0001572616","company_name":"FRACTYL HEALTH, INC.","filed_at":"2025-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.039600+00:00","generated_at":"2026-05-27T04:41:22.791746+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Fractyl Health prioritizes Revita weight maintenance, Rejuva gene therapy; cuts 17% workforce","bullets":["REMAIN-1 pivotal study for weight maintenance post-GLP-1 withdrawal; midpoint data analysis expected Q2 2025, full enrollment summer 2025.","Rejuva gene therapy candidate RJVA-001 completed key preclinical studies; first-in-human studies planned H1 2025.","Pausing Revita T2D programs (REVITALIZE-1 and German Real-World Registry) to focus resources.","Workforce reduction of 22 employees (~17%) with estimated severance costs of $1.8M; cash runway extended into 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-011430","json":"https://secwatch.observer/filing/0000950170-25-011430.json","markdown":"https://secwatch.observer/filing/0000950170-25-011430.md","text":"https://secwatch.observer/filing/0000950170-25-011430.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1572616/000095017025011430/0000950170-25-011430-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1572616/000095017025011430/guts-20250131.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T04:41:22.791746+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e97b41be09582bead894a900e88b0eefa8283c9","claim":"FRACTYL HEALTH, INC. announced a restructuring with charges of approximately $1.8 million affecting the Company (22 employees, or approximately 17% of the Company’s workforce).","evidence_excerpt":"implemented by the second quarter of 2025. In connection with the Strategic Reprioritization, the Company estimates that it will incur cash charges of approximately $1.8 million related to severance, employee benefits, and other related personnel reduction costs. At this time, the Company is unable in good faith to make a determination of other estimated","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1572616/000095017025011430/0000950170-25-011430-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.8 million"},{"label":"Affected area","value":"the Company"},{"label":"Headcount","value":"22 employees, or approximately 17% of the Company’s workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}